< Back to previous page
Researcher
Karen Vanhoorelbeke
- Disciplines:Biochemistry and metabolism, Cardiac and vascular medicine, Medical biochemistry and metabolism
Affiliations
- Chemistry, Kulak Kortrijk Campus (Department)
Responsible
From1 Oct 2018 → Today - Chemistry, Kulak Kortrijk Campus (Department)
Member
From1 Jan 2009 → Today - Faculty of Medicine (Faculty)
Member
From1 Oct 2004 → 30 Sep 2006 - Faculty of Science, Kulak Kortrijk Campus (Faculty)
Member
From1 Oct 2000 → 31 Dec 2008
Projects
41 - 50 of 58
- Immunoprofiling of patients with acquired thrombotic thrombocytopenic purpura: towards identification of prognostic factors.From1 Jan 2015 → 31 Dec 2018Funding: IWT personal funding - strategic basic research grants
- TArget: Immune response in acquired thrombotic thrombocytopenic purport.From1 Oct 2014 → TodayFunding: BOF - Other initiatives
- Developing new treatment strategies for acquired and congenital thrombotic thrombocytopenic purpura.From1 Oct 2014 → 31 Jan 2017Funding: FWO fellowships
- Anti-ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura.From1 Oct 2014 → 30 Sep 2018Funding: BOF - Concerted Research Project from 1994
- State-of-the art tools for non-viral gene therapy: towards long-term correction for von Willebrand disease,From1 Jan 2014 → 31 Dec 2018Funding: IWT personal funding - strategic basic research grants
- Investigation of the role of GARP by using cell specific knockout miceFrom1 Oct 2013 → 12 Sep 2018Funding: Own budget, for example: patrimony, inscription fees, gifts
- Unravelling the role of ADAMTS13 and anti-ADAMTS13 autoantibodies in the pathophysiology of thrombotic thrombocytopenic purpuraFrom1 Oct 2013 → 14 May 2018Funding: Own budget, for example: patrimony, inscription fees, gifts
- Towards novel therapeutic strategies in ischemic stroke by targeting von Willebrand factor and promoting fibrinolysisFrom1 Mar 2013 → 13 Mar 2017Funding: BOF - Doctoral projects
- Specific contribution of transgene plasma and platelet von Willebrand factor in haemostasis and thrombosis: from functional studies to gene therapy.From1 Jan 2012 → 31 Dec 2015Funding: FWO research project (including WEAVE projects)
- C-terminal domains of ADAMTS13: revealing unknown exosites and structure.From1 Jan 2011 → 31 Dec 2014Funding: FWO research project (including WEAVE projects)
Publications
1 - 10 of 210
- Peak ADAMTS13 activity to assess ADAMTS13 conformation and risk of relapse in immune-mediated Thrombotic Thrombocytopenic Purpura.(2024)
Authors: Karen Vanhoorelbeke
Pages: blood.2023 - Open ADAMTS-13 conformation index predicts earlier relapse in immune-mediated thrombotic thrombocytopenic purpura(2024)
Authors: Claudia Tersteeg, Karen Vanhoorelbeke
Pages: 493 - 502 - Management and follow-up of pregnancy-onset thrombotic thrombocytopenic purpura: the French experience(2024)
Authors: Karen Vanhoorelbeke
Pages: 183 - 193 - Hemophagocytic lymphohistiocytosis is associated with deficiency and closed conformation of ADAMTS-13(2024)
Authors: Karen Vanhoorelbeke
- Impact of N-glycan mediated shielding of ADAMTS-13 on the binding of pathogenic antibodies in immune thrombotic thrombocytopenic purpura(2023)
Authors: Karen Vanhoorelbeke
Pages: 3402 - 3413 - FLUIDOT: A case study on drug tolerance screening and antibody mining, one cell at a time(2023)
Authors: Karen Ven, Jolien Breukers, Iene Rutten, Maya Imbrechts, Sam Noppen, Dominique Schols, Paul De Munter, Hendrik Jan Thibaut, Karen Vanhoorelbeke, Dragana Spasic, et al.
- ADAMTS13 and Non-ADAMTS13 Biomarkers in Immune-Mediated Thrombotic Thrombocytopenic Purpura(2023)
Authors: Quintijn Bonnez, Karen Vanhoorelbeke
- Measuring ADAMTS-13 activity to diagnose thrombotic thrombocytopenic purpura: a novel, fast fiber-optic surface plasmon resonance immunoassay(2023)
Authors: Quintijn Bonnez, Peter Verhamme, Claudia Tersteeg, Simon De Meyer, Jeroen Lammertyn, Karen Vanhoorelbeke
- Small-Molecule Cyclophilin Inhibitors Potently Reduce Platelet Procoagulant Activity(2023)
Authors: Simon De Meyer, Karen Vanhoorelbeke, Claudia Tersteeg
- Comparison of ADAMTS13 activity testing platforms for diagnosis and monitoring of thrombotic thrombocytopenic purpura(2023)
Authors: Karen Vanhoorelbeke
Pages: 26 - 26
Patents
1 - 9 of 9
- Haemorrhagic disorder due to ventricular assist device (Inventor)
- Humanised adamts13 binding antibodies (Inventor)
- Screening and sorting of single cells (Inventor)
- Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device (Inventor)
- Humanised adamts13 binding antibodies (Inventor)
- Screening and sorting of single cells (Inventor)
- Haemorrhagic disorder due to ventricular assist device (Inventor)
- Humanised adamts13 binding antibodies (Inventor)
- Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device (Inventor)